Abstract: A golf ball includes a composition producing a unique visible effect to enhance a performance parameter of the golf ball. The golf ball includes a color-shifting cover surrounding a core. The color-shifting cover includes a cover material mixed with a colorant. The cover material includes at least one of a thermoset polyurethane, cast urethane, or ionomer material. The colorant includes one or more of a flake, pigment, or dye. The color-shifting cover includes a visible shift in color based on a change in at least one of incidence of light, temperature, or pressure.

Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.

Abstract: Embodiments of golf club heads, golf clubs, and methods to manufacture golf club heads and golf clubs are generally described herein. In one example, a golf club head may include a body portion having an opening, a face portion coupled to the body portion to close the opening, a mass portion coupled to the body portion, a face support portion coupled to a back surface of the face portion and having a different material than a material of the face portion, and a filler material in the body portion between the face support portion and the mass portion. The filler material comprises a first elasticity and the face support portion comprises a second elasticity less than the first elasticity. A thickness of the face support portion is different from a thickness of the face portion. Other examples and embodiments may be described and claimed.

Abstract: Described herein are benzoxazepin oxazolidinone compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.

Abstract: An extracorporeal blood treatment device and a method are provided for removing a secondary membrane formed on a semipermeable membrane of a dialyzer during an extracorporeal blood treatment. The extracorporeal blood treatment device operates in a first operating mode in which a dialysate outlet valve is open such that dialysate flows through a dialyzer feed line, through a dialysate chamber, and into and through a dialyzer discharge line. The extracorporeal blood treatment device operates in a second operating mode to remove the secondary membrane from the semipermeable membrane. During the second operating mode, the dialysate outlet valve is closed for a duration of time such that dialysate is prevented from flowing through the dialyzer discharge line. A backflush procedure results wherein a volume of dialysate passes from the dialysate chamber through the semipermeable membrane and into the blood chamber.

Abstract: The present disclosure relates to certain AHR agonist compounds, their method of making, and to pharmaceutical compositions comprising the compounds and to methods of using the compounds to treat immune-mediated diseases, such as psoriasis and atopic dermatitis.

Abstract: Processes and devices provide parenteral delivery of therapeutic fluids, in particular high-viscosity therapeutic fluids (e.g., protein therapeutics), by a chemical reaction that generates a gas. A device may include a first actuation chamber containing a first reagent, a second reaction chamber containing a second reagent, and a third therapeutic fluid chamber containing the therapeutic fluid. In a loaded configuration, a plunger separates the first chamber from the second chamber. In a delivery configuration, the plunger allows the first reagent from the first chamber to communicate and react with the second reagent from the second chamber. The generated gas acts upon a plunger to deliver the therapeutic fluid from the third chamber.

Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.

Abstract: The present disclosure relates to a dose detection system for use with a medication delivery device in which a dose setting member rotates relative to an actuator during dose delivery. The dose detection system includes a module which is removably attached to the medication delivery device. The module includes a rotation sensor attached to the actuator during dose delivery. A sensed element is attached to the dose setting member and includes surface features detectable by the rotation sensor. The rotation sensor comprises a following member including a contact portion resting against and spring-biased in the direction of the surface features. The contact surface is positioned to move over the surface features during rotation of the sensed element, and the rotation sensor is responsive to the movement of the contact portion over the surface features to detect the rotation of the dose setting member.

Abstract: Provided is 5-(3-chloro-4-fluorophenyl)-7-cyclopropyl-3-(2-(3-fluoro-3-methylazetidin-1-yl)-2-oxoethyl)-3,7-dihydro-4H-pyrrolo [2,3-d]pyrimidin-4-one and pharmaceutically acceptable salts thereof, and their uses in the treatment of psychiatric, neurological, and neurodevelopmental disorders, as well as diseases of the nervous system.

Abstract: A method of performing a vascular procedure can include providing a multi-catheter assembly including a first subset of interventional devices and a second subset of interventional devices detachably couplable to the first subset of interventional devices, coupling the first subset of interventional devices to a robotic drive system, robotically driving the multi-catheter assembly to achieve supra-aortic access while the second subset of interventional devices is coupled to the first subset of interventional devices, uncoupling the second subset of interventional devices from the first subset of interventional devices, manually driving the second subset of interventional devices to a procedure site, and performing a vascular procedure using the second subset of interventional devices.

Abstract: Synthesis techniques are described for forming organotin trialkoxide compounds via direct alkylation of tin alkoxides. A first method involves reacting an alkali metal tin trialkoxide with an organohalide compound (RXn, where X is a halide atom and n?1) to form a monoorgano tin trialkoxide represented by the formula R[Sn(OR?)3]n. The method can be used to form polytin trialkoxide compounds with a plurality of radiation sensitive C—Sn bonds. R and R? include organo groups and can optionally comprise hetero-atoms and/or unsaturated bonds. A second method involves the ultraviolet light-driven reaction of a di-tin tetraalkoxide with an organohalide compound (RX) to form a monoorgano trialkoxide represented by the formula RSn(OR?)3. A third method involves the visible or ultraviolet light-driven reaction of a di-tin tetraalkoxide or an alkali metal tin trialkoxide with an fluorinated organohalide compound (RFX) to form a fluorinated monoorgano trialkoxide represented by the formula RFSn(OR?)3.

Abstract: A pneumatic tire comprising non-ground contacting tire components each independently formed from a rubber composition comprising greater than 89% sustainable material content.

Abstract: A fire suppressant for cooling a battery pack includes a pressurized mixture of a dry chemical and carbon dioxide. The dry chemical is an inorganic particulate chemical. The dry chemical particles are small enough to be carried by a flow of depressurizing carbon dioxide. A mass of the dry chemical is between 5% and 50% of a mass of the carbon dioxide. The carbon dioxide, when depressurized, vaporizes and cools the dry chemical and the battery pack. The dry chemical can adhere to the battery pack when the mixture is depressurized. An amount of the fire suppressant used to cool the battery pack is equal to or greater than an inerting volume of fire suppressant for the battery pack.

Abstract: Bioprocess control systems, computing devices, hardware architectures, modules, libraries and graphical user interfaces. More specifically, bioprocessing instrument control system modules, libraries and user interfaces used to control bioprocessing instruments and biological processes are disclosed. A computing device(s) having a display and functional graphical user interface configured to receive input from a user, includes a primary selection area with at least one virtual input to control operation of a bioprocessing instrument set to generate a cell based therapeutic and a secondary selection area with at least one virtual output indicating a process state and/or a device state of an instrument contained in a bioprocessing instrument set.

Abstract: A clutch assembly, such as a dynamically controllable clutch (“DCC”), having an actuator for controlling coupling members for engagement and disengagement of power components. The actuator includes a cylindrical cam member with an end face extending transversely to a rotational axis of the cam member. The end face has a first cam surface and a second cam surface. The first cam surface is radially spaced from and adjacent to the second cam surface. A first cam follower follows the first cam surface and a second cam follower follows the second cam surface. A first link extends between the first cam follower and a first coupling member, and a second link extends between the second cam follower and a second coupling member.

Abstract: Embodiments of the present disclosure are directed to a plurality of nucleotide sequences encoding a first intein fused to at least a portion of a first transcription activator-like effector (TALE), a second nucleotide sequence encoding the first intein fused to at least a portion of a second TALE, and a third nucleotide sequence encoding a second intein fused to at least a portion of a rare-cutting nuclease.

Abstract: A method is described for the production of a polyhydric alcohol from a urethane containing polymer. The method first provides a reaction mixture comprising said polymer, a solvent, which comprises a polyol capable of reacting with said polymer to depolymerize said polymer; and a catalyst, which comprises catalyst particles. Said polymer is depolymerized in said reaction mixture by reacting with said polyol to produce said polyhydric alcohol. A further step allows said reaction mixture containing said polyhydric alcohol product to separate into an, upper, product phase containing said polyhydric alcohol and another, lower, phase mainly containing said polyol and said catalyst. The catalyst is recovered from said another phase, while said polyhydric alcohol product is recovered from said product phase.

Abstract: An illustrative medical imaging system includes an imaging device and an image processing system communicatively coupled to the imaging device. The imaging device includes an image sensor configured to capture a two-dimensional visible light image of a scene and a depth sensor separate from the image sensor and configured to generate a depth map of the scene. The image processing system is configured to generate, based on the two-dimensional visible light image of the scene captured by the image sensor and the depth map of the scene generated by the depth sensor, two perspective images of the scene that, when presented concurrently by a stereo viewer, form a stereoscopic view of the scene.

Abstract: A method of manufacturing a non-fibrous water soluble product comprising particles, comprising: a) providing a first continuous water soluble non-fibrous substrate comprising a first side and moving in a first direction, b) providing a discretizing unit comprising one or more pockets comprising an opening; c) providing a continuous feed of first particles to at least one of the one or more pockets of the discretizing unit through the pocket opening at least partially filling the at least one of the one or more pockets, d) delivering the first particles from the pocket through the opening onto a portion of the first side of the first continuous water soluble non-fibrous substrate, and e) at least partially covering the first side of the first continuous water soluble non-fibrous substrate.